Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abraham Fong

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Pediatric Hematology and Oncology|December 4, 2009
High-risk neuroblastoma: a therapy in evolutionAbraham Fong, Julie R Park
The Journal of Biological Chemistry|May 8, 2002
Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inducible processing of NF-kappa B2/p100Abraham Fong, Shao-Cong Sun
The Journal of Biological Chemistry|May 14, 2004
Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylationGutian Xiao, Abraham Fong, Shao-Cong Sun
The Journal of Biological Chemistry|August 20, 2002
S9, a 19 S proteasome subunit interacting with ubiquitinated NF-kappaB2/p100Abraham Fong, Minying Zhang, John Neely, et al.
Lung Cancer (Amsterdam, Netherlands)|May 22, 2020
SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 studyDaniel Morgensztern, Melissa Johnson, Charles M Rudin, et al.
Journal of Pediatric Hematology/Oncology|May 7, 2008
Maternal T-cell engraftment associated with severe hemophagocytosis of the bone marrow in untreated X-linked severe combined immunodeficiencyChristopher C Dvorak, Amanda Sandford, Abraham Fong, et al.
Gynecologic Oncology|June 10, 2020
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 studyErika Hamilton, David M O'Malley, Roisin O'Cearbhaill, et al.
Blood|October 18, 2017
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HLJonathan W Friedberg, Andres Forero-Torres, Rodolfo E Bordoni, et al.
Blood|July 20, 2016
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphomaRobert Chen, Ajay K Gopal, Scott E Smith, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Pediatric Hematology and Oncology|December 4, 2009
High-risk neuroblastoma: a therapy in evolutionAbraham Fong, Julie R Park
The Journal of Biological Chemistry|May 8, 2002
Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inducible processing of NF-kappa B2/p100Abraham Fong, Shao-Cong Sun
The Journal of Biological Chemistry|May 14, 2004
Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylationGutian Xiao, Abraham Fong, Shao-Cong Sun
The Journal of Biological Chemistry|August 20, 2002
S9, a 19 S proteasome subunit interacting with ubiquitinated NF-kappaB2/p100Abraham Fong, Minying Zhang, John Neely, et al.
Lung Cancer (Amsterdam, Netherlands)|May 22, 2020
SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 studyDaniel Morgensztern, Melissa Johnson, Charles M Rudin, et al.
Journal of Pediatric Hematology/Oncology|May 7, 2008
Maternal T-cell engraftment associated with severe hemophagocytosis of the bone marrow in untreated X-linked severe combined immunodeficiencyChristopher C Dvorak, Amanda Sandford, Abraham Fong, et al.
Gynecologic Oncology|June 10, 2020
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 studyErika Hamilton, David M O'Malley, Roisin O'Cearbhaill, et al.
Blood|October 18, 2017
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HLJonathan W Friedberg, Andres Forero-Torres, Rodolfo E Bordoni, et al.
Blood|July 20, 2016
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphomaRobert Chen, Ajay K Gopal, Scott E Smith, et al.
Pageof 1